<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935450</url>
  </required_header>
  <id_info>
    <org_study_id>398-20</org_study_id>
    <nct_id>NCT04935450</nct_id>
  </id_info>
  <brief_title>Pulmonary Inflammation in COVID-19 ARDS</brief_title>
  <acronym>IMPU-COVID</acronym>
  <official_title>Pulmonary Inflammation Profiles in COVID-19 Related ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients older than 18 years of age, with COVID-19 related ARDS (C-ARDS) hospitalized in the&#xD;
      ICU and invasively mechanically ventilated will be included in the study.&#xD;
&#xD;
      This is an observational cohort study. After informed consent by the next of kin, and within&#xD;
      the first 72 hours of invasive mechanical ventilation a blood and a Broncho Alveolar Lavage&#xD;
      Fluid (BALF) sample will be collected. If the patients remain invasively mechanically&#xD;
      ventilated a second and third blood and BALF sample will be collected every 7-10 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the core study is to measure a number of biochemical, cellular and&#xD;
      inflammatory mediators in the BALF of C-ARDS patients and evaluate their correlation with the&#xD;
      course of disease in terms of respiratory mechanics, complications and outcomes.&#xD;
&#xD;
      The mediators selected have been previously used in ARDS investigation to attempt prognostic&#xD;
      and predictive enrichment.&#xD;
&#xD;
      Patients hospitalized in the ICU following C-ARDS and requiring invasive mechanical&#xD;
      ventilation will be candidates for enrollment.&#xD;
&#xD;
      Patients enrolled in the study (Informed consent obtained from next of kin) will be subject&#xD;
      to the realization of optic bronchoscopy within the first 72 h of mechanical ventilation to&#xD;
      obtain BALF for analysis. A second and third bronchoscopy and sampling of BALF will be&#xD;
      performed every 7-10 days if mechanical ventilation and the clinical conditions allow it. A&#xD;
      sample of whole blood will be taken contemporary to each bronchoscopy in order to perform&#xD;
      parallel measurements (lungs and peripheral blood). Patients will be followed up until&#xD;
      hospital discharge.&#xD;
&#xD;
      BALF samples will be divided to perform different analysis in the immunology, cytology and&#xD;
      microbiology labs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2020</start_date>
  <completion_date type="Anticipated">August 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Correlation of BALF and Blood mediators with ICU mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory mechanics</measure>
    <time_frame>Day 0 (after study inclusion) and every day up to 3 months</time_frame>
    <description>Correlation of BALF and Blood mediators with respiratory mechanics during invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BALF PCR</measure>
    <time_frame>Day 0 (performance of first BALF sample) Day 8, Day 16</time_frame>
    <description>Semiquant PCR of SARS-CoV-2 in bronchoalveolar lavage fluid, comparison with contemporary PCR in Blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BALF characteristics</measure>
    <time_frame>Day 0 (performance of first BALF sample) Day 8, Day 16</time_frame>
    <description>Cellular populations in BALF and their change over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BALF cytoquines</measure>
    <time_frame>Day 0 (performance of first BALF sample) Day 8, Day 16</time_frame>
    <description>Cytoquines in BALF and change over time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Mortality in hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Health related quality of life via SF-36 questionnaire</measure>
    <time_frame>Up to 3 months</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2</condition>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bronchoalveolar lavage</intervention_name>
    <description>Low volume Broncho alveolar lavage. During optic flexible bronchoscopy through the tracheal tube or the tracheostomy cannula a maximum of 4 aliquots of 20 ml normal saline will be instilled in a wedged position in the right medium lobe of the patients and then aspirated untill reaching a total of 25ml of fluid (BALF) for analysis</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bronchoalveolar Lavage Fluid samples Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 ARDS ICU patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  COVID-19 related ARDS&#xD;
&#xD;
          -  Hospitalized in ICU&#xD;
&#xD;
          -  Invasive mechanical ventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunocompromised for previous condition&#xD;
&#xD;
          -  transplanted patients&#xD;
&#xD;
          -  Known pulmonary bacterial co-infection at the time of admission to the ICU&#xD;
&#xD;
          -  Contraindication to the realization of Bronchoscopy (Itracranial Hypertension, severe&#xD;
             hypoxaemia with P/F &lt; 80, severe hemodynamic instability, severe arrhythmia, non&#xD;
             correctable coagulopathy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TOMMASO BARDI, MD</last_name>
    <phone>+34640350484</phone>
    <email>tommaso.bardi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TOMMASO BARDI, MD</last_name>
      <phone>+34640350484</phone>
      <email>tommaso.bardi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Tommaso Bardi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Broncho Alveolar Lavage</keyword>
  <keyword>Pulmonary Inflammation</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <keyword>Respiratory Mechanics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

